Green Valley Pharmaceutical
Sandeep Agnihotri is a seasoned researcher with extensive experience in biochemistry and molecular biology. Currently serving as a Senior Research Officer at Shanghai Green Valley Pharmaceutical CO.,LTD since November 2020, Sandeep previously worked as a Postdoctoral Researcher at the Institute of Neuroscience (ION) under the Chinese Academy of Sciences, focusing on Cancer Associated Fibroblast cells and their implications in cancer biology. Additional postdoctoral experiences include work at Harbin Institute of Technology, investigating the role of PINK1 protein in neurogenesis related to Parkinson's disease, and a Senior Research Fellow position at Jawaharlal Nehru University, where Sandeep contributed to cancer research involving autophagy and tumorigenesis. Sandeep earned a Doctorate in Biochemistry and Molecular Biology from Jawaharlal Nehru University in 2013, following a Master’s degree in Biotechnology from the University of Allahabad and a Bachelor's degree in Life Sciences from Bundelkhand University.
This person is not in any teams
Green Valley Pharmaceutical
Shanghai Green Valley Pharmaceuticals is an innovative Chinese pharmaceutical company founded in 1997 that pioneers carbohydrate drug development and new treatment strategies in the areas of chronic and complex diseases. It is focused on advancing research programs in neuropsychiatric diseases, cancer, cardiovascular diseases, metabolic diseasesand autoimmune diseases. It has 1,500 employees in China and operates a subsidiary in the United States. It has built the large-scale carbohydrate compound library, the carbohydrate drug API and processing facility, and the world's leading R&D pipeline for carbohydrate drug products.The company upholds the sacred mission of "developing medicines that fulfill the biggest unmet medical needs for human health", explores the pathogenesis of chronic and complex diseases with a holistic view of treatment, and focuses on breakthrough innovation in research and development of carbohydrate drugs. Green Valley is committed to becoming a global leader in carbohydrate drug innovation, providing safer and more effective drugs for patients with chronic and complex diseases, and providing better choice of treatment for diseases and improving the quality of life.